![Oncologists, advocates, FDA call for an end to MTD and the “more is better” era in cancer drug dosing](https://cdn.cancerletter.com/media/2022/04/29132656/48-17-MTD-4x3-1.jpg)
![Oncologists, advocates, FDA call for an end to MTD and the “more is better” era in cancer drug dosing](https://cdn.cancerletter.com/media/2022/04/29132656/48-17-MTD-4x3-1.jpg)
Cover Story
Clinical
By Alice Tracey
For decades, pinpointing the highest dose of a drug that cancer patients could tolerate was the first step investigators were required to take before moving into phase II and III clinical trials.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- Trump et al. are wrong: Biden Cancer Initiative is not to be confused with the Beau Biden Cancer Moonshot
- Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82
- A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.